CY1123723T1 - Μη ανθρωπινα ζωα που φερουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 274 - Google Patents

Μη ανθρωπινα ζωα που φερουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 274

Info

Publication number
CY1123723T1
CY1123723T1 CY20201101215T CY201101215T CY1123723T1 CY 1123723 T1 CY1123723 T1 CY 1123723T1 CY 20201101215 T CY20201101215 T CY 20201101215T CY 201101215 T CY201101215 T CY 201101215T CY 1123723 T1 CY1123723 T1 CY 1123723T1
Authority
CY
Cyprus
Prior art keywords
human animals
complex
dehumanized
animals carrying
differentiation gene
Prior art date
Application number
CY20201101215T
Other languages
Greek (el)
English (en)
Inventor
Elena BUROVA
Yajun Tang
Ka-Man Venus Lai
Andrew J. Murphy
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of CY1123723T1 publication Critical patent/CY1123723T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY20201101215T 2014-12-09 2020-12-23 Μη ανθρωπινα ζωα που φερουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 274 CY1123723T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Publications (1)

Publication Number Publication Date
CY1123723T1 true CY1123723T1 (el) 2022-03-24

Family

ID=55024286

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101215T CY1123723T1 (el) 2014-12-09 2020-12-23 Μη ανθρωπινα ζωα που φερουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 274

Country Status (27)

Country Link
US (4) US9913461B2 (enExample)
EP (3) EP3230320B1 (enExample)
JP (3) JP2018500896A (enExample)
KR (2) KR102316842B1 (enExample)
CN (2) CN107257624B (enExample)
AU (3) AU2015360667B2 (enExample)
BR (1) BR112017011982A2 (enExample)
CA (1) CA2968675C (enExample)
CY (1) CY1123723T1 (enExample)
DK (2) DK3230320T3 (enExample)
ES (2) ES2841353T3 (enExample)
FI (1) FI3808775T3 (enExample)
HR (2) HRP20240855T1 (enExample)
HU (2) HUE052606T2 (enExample)
IL (3) IL282649B (enExample)
LT (2) LT3230320T (enExample)
MX (1) MX2017007636A (enExample)
NZ (2) NZ770783A (enExample)
PL (1) PL3808775T3 (enExample)
PT (2) PT3808775T (enExample)
RS (2) RS61218B1 (enExample)
RU (1) RU2711729C2 (enExample)
SG (2) SG10202100792XA (enExample)
SI (2) SI3808775T1 (enExample)
SM (2) SMT202100148T1 (enExample)
WO (1) WO2016094481A1 (enExample)
ZA (1) ZA201703263B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2841353T3 (es) * 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
WO2017136712A1 (en) 2016-02-04 2017-08-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered angptl8 gene
CN109068621B (zh) 2016-02-29 2021-07-20 再生元制药公司 具有人源化的tmprss基因的啮齿类动物
US10912287B2 (en) 2016-06-28 2021-02-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd Genetically modified mice expressing humanized PD-1
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
RS67792B1 (sr) 2016-12-01 2026-03-31 Regeneron Pharma Radio-obeležena anti-pd-l1 antitela za imuno-pet snimanje
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
WO2019072241A1 (en) * 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
JP7361031B2 (ja) 2017-11-30 2023-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化ｔｒｋｂ遺伝子座を含む非ヒト動物
WO2019114768A1 (en) 2017-12-12 2019-06-20 Biocytogen Jiangsu Co., Ltd. GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e
IL277355B2 (en) 2018-03-26 2025-01-01 Regeneron Pharma Humanized rodents for testing therapeutic agents
CA3098040A1 (en) 2018-07-16 2020-01-23 Regeneron Pharmaceuticals, Inc. Non-human animal models of ditra disease and uses thereof
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
WO2020081585A1 (en) * 2018-10-15 2020-04-23 The Brigham And Women's Hospital, Inc. The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
WO2022174823A1 (en) * 2021-02-19 2022-08-25 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animal with human or chimeric cd3 genes
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
WO2002000692A2 (en) 2000-06-28 2002-01-03 Genetics Institute, Llc. Pd-l2 molecules: pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
WO2004060053A2 (en) * 2002-12-16 2004-07-22 Genentech, Inc. Transgenic mice expressing human cd20
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
AU2004304665B2 (en) 2003-12-24 2009-03-12 Novo Nordisk A/S Transgenic non-human mammal comprising a polynucleotide encoding human or humanized C5aR
ATE510020T1 (de) 2003-12-24 2011-06-15 G2 Inflammation Pty Ltd Transgenes nichtmenschliches säugetier mit einem polynukleotid, das für human-c5ar oder humanisiertes c5ar codiert
PL1810026T3 (pl) 2004-10-06 2018-08-31 Mayo Foundation For Medical Education And Research B7-H1 i PD-1 w leczeniu raka nerkowokomórkowego
EP1802193B1 (en) 2004-10-19 2014-04-30 Regeneron Pharmaceuticals, Inc. Method for generating a mouse homozygous for a genetic modification
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
EP2889309B1 (en) 2006-03-03 2017-12-27 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of pd-1 or pd-l1
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX340972B (es) 2008-10-08 2016-08-02 Intrexon Corp Celulas manipuladas por ingenieria que expresan multiples inmunomoduladores, y uso de las mismas.
KR101711222B1 (ko) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 인간화 항체들을 발현하는 비-인간 유전자이식 동물들 및 그의 이용
WO2010089411A2 (en) 2009-02-09 2010-08-12 Universite De La Mediterranee Pd-1 antibodies and pd-l1 antibodies and uses thereof
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
WO2011020014A1 (en) 2009-08-14 2011-02-17 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
IN2012DN01769A (enExample) * 2009-08-28 2015-06-05 Vlst Corp
EP4502152A3 (en) 2009-10-06 2025-04-30 Regeneron Pharmaceuticals, Inc. Genetically modified mice and engraftment
US20120263692A1 (en) 2009-11-16 2012-10-18 Bertone Alicia L Engineered Xenogeneic Cells for Repair of Biological Tissue
EP3279215B1 (en) * 2009-11-24 2020-02-12 MedImmune Limited Targeted binding agents against b7-h1
EP3498730B1 (en) * 2009-12-21 2026-01-28 Regeneron Pharmaceuticals, Inc. Humanized fc gamma r mice
EP3578657B1 (en) * 2010-04-06 2024-03-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of cd274/pd-l1 gene
PT4233537T (pt) * 2011-02-15 2025-09-08 Regeneron Pharma Ratinhos humanizados para m-csf e utilizações dos mesmos
RS63220B1 (sr) 2011-10-28 2022-06-30 Regeneron Pharma Genetski modifikovani miševi sa ekspresijom himernih molekula klase ii glavnog kompleksa histokompatibilnosti (mhc)
KR102295746B1 (ko) 2011-10-28 2021-09-01 리제너론 파아마슈티컬스, 인크. 유전자 변형된 주요 조직적합성 복합체 마우스
SI2818478T1 (sl) 2011-10-28 2017-07-31 Regeneron Pharmaceuticals, Inc. Humanizirani il-6 in receptor il-6
WO2013078230A1 (en) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
KR102502640B1 (ko) * 2012-08-21 2023-02-23 사노피 바이오테크놀로지 Il-4r 길항제의 투여에 의한 천식의 치료 또는 예방 방법
KR102241962B1 (ko) 2012-09-07 2021-04-20 예일 유니버시티 유전적으로 변형된 비-인간 동물 및 이것들의 사용 방법
DK4389764T3 (da) 2012-11-05 2026-04-13 Regeneron Pharma Genetisk modificerede gnavere og fremgangsmåder til anvendelse heraf
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
US9848587B2 (en) * 2013-02-20 2017-12-26 Regeneron Pharmaceuticals, Inc. Humanized T cell co-receptor mice
MX2015010841A (es) 2013-02-20 2016-05-09 Regeneron Pharma Modificacion genetica de ratas.
SI2958937T1 (sl) * 2013-02-22 2018-12-31 Regeneron Pharmaceuticals, Inc. Miš, ki izraža humanizirani poglavitni histokompatibilnostni kompleks
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
DK3456831T3 (da) 2013-04-16 2021-09-06 Regeneron Pharma Målrettet modifikation af rottegenom
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
AU2014275166B2 (en) 2013-06-06 2020-09-10 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using PD-L1 isoforms
HRP20231121T1 (hr) 2013-09-23 2023-12-22 Regeneron Pharmaceuticals, Inc. Životinje koje nisu ljudi, koje imaju gen za humanizirani protein koji regulira signale
MY183188A (en) 2013-11-19 2021-02-18 Regeneron Pharma Non-human animals having a humanized b-cell activating factor gene
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
RS60398B1 (sr) 2014-04-08 2020-07-31 Regeneron Pharma Ne-humane životinje sa humanizovanim fc-gama receptorima
NO2785538T3 (enExample) 2014-05-07 2018-08-04
EP3482629B1 (en) 2014-05-19 2020-11-25 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals expressing human epo
WO2015196051A1 (en) * 2014-06-19 2015-12-23 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized programmed cell death 1 gene
BR112017010793A2 (pt) 2014-11-24 2017-12-26 Regeneron Pharma animal não humano geneticamente modificado, camundongo, métodos para produzir um animal não humano geneticamente modificado e de triagem de candidatos a fármaco direcionados a um antígeno de interesse, e, modelo de camundongo.
BR112017010490A2 (pt) 2014-12-05 2018-04-03 Regeneron Pharma roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
ES2841353T3 (es) * 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
CN108366548B (zh) 2015-11-20 2021-10-08 瑞泽恩制药公司 具有人源化淋巴细胞活化基因3的非人动物
WO2018041118A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric pd-l1

Also Published As

Publication number Publication date
US20240389563A1 (en) 2024-11-28
JP2018500896A (ja) 2018-01-18
KR102457921B1 (ko) 2022-10-25
NZ770783A (en) 2024-11-29
EP4399969A3 (en) 2024-10-30
NZ731954A (en) 2024-11-29
KR20210130251A (ko) 2021-10-29
PT3808775T (pt) 2024-07-09
EP3808775A1 (en) 2021-04-21
CN113412818A (zh) 2021-09-21
ES2982515T3 (es) 2024-10-16
US9913461B2 (en) 2018-03-13
JP2021003130A (ja) 2021-01-14
CA2968675C (en) 2023-10-17
LT3808775T (lt) 2024-07-10
EP4399969A2 (en) 2024-07-17
HRP20240855T1 (hr) 2024-10-11
HUE052606T2 (hu) 2021-05-28
WO2016094481A1 (en) 2016-06-16
AU2025204751A1 (en) 2025-07-17
SMT202100148T1 (it) 2021-05-07
IL282649B (en) 2022-07-01
US12089575B2 (en) 2024-09-17
KR20170101910A (ko) 2017-09-06
RU2711729C2 (ru) 2020-01-21
CN107257624A (zh) 2017-10-17
SI3230320T1 (sl) 2021-02-26
JP7488861B2 (ja) 2024-05-22
DK3808775T3 (da) 2024-07-01
RS61218B1 (sr) 2021-01-29
SMT202400313T1 (it) 2024-09-16
US20210105983A1 (en) 2021-04-15
FI3808775T3 (fi) 2024-07-02
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
US20180160663A1 (en) 2018-06-14
RU2017123754A (ru) 2019-01-10
US20160157469A1 (en) 2016-06-09
SG11201703931QA (en) 2017-06-29
RS65664B1 (sr) 2024-07-31
AU2021286369B2 (en) 2025-03-27
IL252695B (en) 2020-07-30
CN113412818B (zh) 2022-11-04
AU2015360667B2 (en) 2021-09-23
PL3808775T3 (pl) 2024-08-19
IL252695A0 (en) 2017-08-31
IL275864A (en) 2020-08-31
MX2017007636A (es) 2018-03-28
DK3230320T3 (da) 2021-01-11
SI3808775T1 (sl) 2024-08-30
AU2021286369A1 (en) 2022-01-20
PT3230320T (pt) 2021-01-08
JP7145920B2 (ja) 2022-10-03
HUE067123T2 (hu) 2024-10-28
EP3808775B1 (en) 2024-04-17
LT3230320T (lt) 2021-01-11
ES2841353T3 (es) 2021-07-08
SG10202100792XA (en) 2021-03-30
IL275864B (en) 2021-05-31
AU2015360667A1 (en) 2017-06-08
HRP20202034T1 (hr) 2021-02-19
EP3230320B1 (en) 2020-10-07
ZA201703263B (en) 2023-02-22
BR112017011982A2 (pt) 2018-01-16
US10881086B2 (en) 2021-01-05
IL282649A (en) 2021-06-30
RU2017123754A3 (enExample) 2019-06-24
KR102316842B1 (ko) 2021-10-25
JP2022184973A (ja) 2022-12-13
EP3230320A1 (en) 2017-10-18

Similar Documents

Publication Publication Date Title
CY1124089T1 (el) Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο συμπλεγματος διαφοροποιησης 47
CY1122940T1 (el) Μη ανθρωπινα ζωα που εχουν ενα εξανθρωπισμενο γονιδιο προγραμματισμενου κυτταρικου θανατου 1
CY1124171T1 (el) Μη ανθρωπινα ζωα με εξανθρωπισμενο γονιδιο ενεργοποιησης λεμφοκυτταρων 3
MX2017007636A (es) Animales no humanos que tienen un gen del grupo de diferenciacion 274 humanizado.
CY1121410T1 (el) Μη-ανθρωπινα ζωα που εχουν ενα εξανθρωποποιημενο γονιδιο ρυθμιστικης πρωτεϊνης σηματος
CY1123714T1 (el) Μη-ανθρωπινα ζωα που εκφραζουν ανθρωποποιημενο cd3 συμπλοκο
IL271454A (en) High-throughput single-cell sequencing with reduced amplification bias
DK3348571T3 (da) Enkeltdomæne-antistof mod programmed death ligand (pd-l1) og deraf afledt protein
IL261979A (en) Mammalian cell line for protein production and library generation
IL262361A (en) Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
DK3507373T3 (da) Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1
MX2016016713A (es) Procesos y sistemas para el montaje de secuencias de acido nucleico.
HUE063481T2 (hu) Hõmérséklet mérése tömbökben tumorkezelõ mezõk (TTFields) szállítására
EP3451856A4 (en) METHOD FOR PRODUCING AND USING MYCELIED PROTEINARY FOOD COMPOSITIONS
EP3294774C0 (en) AFUCOSYLATED PROTEINS, CELL EXPRESSING THIS PROTEIN AND RELATED METHODS
NZ738689A (en) Engineered crispr-cas9 compositions and methods of use
HUE071253T2 (hu) Programozott sejthalál 1 (PD-1) elleni monoklonális antitestek
EP3507302A4 (en) CONDITIONS ACTIVE POLYPEPTIDES AND METHOD FOR THE PRODUCTION THEREOF
EP3273993A4 (en) Genetically modified nk-92 cells and monoclonal antibodies for the treatment of cancer
EP3507373A4 (en) GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERAL PD-L1
SG10201900003WA (en) Non-human animals having a humanized b-cell activating factor gene
MY183189A (en) Non-human animals having a humanized a proliferation-inducing ligand gene
IL272911A (en) Antibodies to programmed cell death protein 1 (PD-1)
WO2014140927A8 (en) Proteins with modified glycosylation and methods of production thereof
EP3472354A4 (en) NUCLEIC ACID ACTIONS AND RELATED PROCEDURES AND COMPOSITIONS